Alvotech Says Adalimumab Story Is ‘Still Being Written’ Ahead Of ‘Critical’ Inspection
Company Confirms It Has Resubmitted Teva-Partnered AVT02 Humira Rival In US
With Alvotech once again asking the US FDA to approve its AVT02 high-concentration interchangeable adalimumab candidate after multiple knockbacks, the company says that the opportunity has not passed as the story of Humira biosimilars is “still being written.”
You may also be interested in...
Alvotech has appointed a fresh chief operating officer as it continues to pursue a US approval for its adalimumab biosimilar. Meanwhile, Strides Pharma Science’s strategy head has left the company and Nick Haggar has joined Biocon’s board, while US association the AAM has also welcomed new staff.
Egypt has become the latest market in which Alvotech has received approval for its AVT02 biosimilar adalimumab rival to Humira. The product will be marketed by MENA partner Bioventure.
Alvotech has its eyes on raising more cash to fund operations and ease the pain of missing out on an FDA approval for its Teva-partnered Humira (adalimumab) biosimilar.